APPROXIMATELY 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed/refractory forms of the disease (R/R DLBCL). With effective forms of treatment currently lacking, there is an increasing need for the development of novel therapies to successfully treat the disease. This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.
EMJ Hematology 9 [Supplement 6] . 2021
November 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/07/Filgrastim-Prophylaxis-for-Neutropenia-in-Myelodysplasia-Pre-Surgery-Case-Report-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Diffuse-Large-B-Cell-Lymphoma-of-Spleen-A-Key-Differential-of-Nodular-Splenomegaly-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/The-Impact-of-‘Pre-conception-on-Conception-An-Inadvertent-Form-of-Infertility-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Hema_Article_Waheed-940x564.jpg)